NCT03616392 is a Phase 1 clinical trial of D308, CKD-501 in Diabetes Mellitus, Type II, sponsored by Chong Kun Dang Pharmaceutical.

Who is sponsoring NCT03616392?

NCT03616392 is sponsored by Chong Kun Dang Pharmaceutical.

What drugs are being tested in NCT03616392?

Interventions in NCT03616392: D308, CKD-501.

What condition does NCT03616392 study?

NCT03616392 studies Diabetes Mellitus, Type II.

Is NCT03616392 still recruiting?

NCT03616392 is currently completed. Last updated 19 November 2018.

Last reviewed 2018-11-19 · How we verify

NCT03616392

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308

Completed Phase 1 Last updated 19 November 2018

What this trial tests

Phase 1 trial testing D308, CKD-501 in Diabetes Mellitus, Type II in 41 participants. Completed in 13 November 2018.

Timeline

25 July 2018

Primary endpoint
17 September 2018

13 November 2018

Quick facts

Lead sponsor	Chong Kun Dang Pharmaceutical
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	25 July 2018
Primary completion	17 September 2018
Estimated completion	13 November 2018
Sites	1 location across South Korea

Drugs / interventions tested

D308, CKD-501 — full drug profile →

Conditions studied

Diabetes Mellitus, Type II — all drugs for Diabetes Mellitus, Type II →

Sponsor

Chong Kun Dang Pharmaceutical — full company profile →

Who can join

19 and older, any sex, with Diabetes Mellitus, Type II. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1 trial to evaluate the drug drug interaction of CKD-501 and D308

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type II

Currently open trials in the same condition.

NCT06846411 — The EMPA-FIT Study · Phase 4 · recruiting

Other Chong Kun Dang Pharmaceutical trials

Trials by the same sponsor.

NCT07404735 — A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 · Phase 1 · not yet recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
NCT07258745 — Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-appro · Phase 1 · recruiting
NCT07304726 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers · Phase 1 · completed
NCT07304700 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03616392 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chong Kun Dang Pharmaceutical
Last refreshed: 19 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03616392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing